Reported side effects are rare and typically mild temporary redness or irritation at the application site, usually resolving quickly No documented systemic toxicity in research literature at typical therapeutic doses European Medicines Agency and independent research groups rate it as well-tolerated Compatible with most standard skincare routines when used with appropriate spacing from incompatible actives Contraindications and cautions Known sensitivity or allergy to copper compounds: avoid use Active skin infections or open wounds at the injection site: delay treatment Pregnancy and breastfeeding: insufficient safety data
Amino acid profile and content in crude herbal drugs (fruits) of rosaceae species
For best results, allow both the vial and solvent to reach ambient laboratory temperature prior to reconstitution
Ongoing Monitoring: The 12-Week and 24-Week Panels After clearing the 4-week gate, patients on stable doses transition to monitoring every 8 to 12 weeks
hospitals Watch our 30-Sec Overview: PharmaVoice Genetic Engineering & Biotechnology News Biotechnology #SXTP #BiotechStocks #FDA #ClinicalTrials #HealthcareInnovation #TickBorneDiseases #Investing #Pharma #FinancialNews 60 Degrees Pharmaceuticals (NASDAQ: SXTP): Early Babesiosis Progress and a $245M+ Market Opportunity To view or add a comment, sign in 60 Degrees Pharmaceuticals, INC (Nasdaq: SXTP): Advancing Breakthrough Tick-Borne Disease Treatment Tick-borne infections like babesiosis are rising rapidly, and 60 Degrees Pharmaceuticals, INC is at the forefront of developing a first-in-class therapy with major market potential
